Entrada Therapeutics, Inc. announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. As President and CEO of CARGO Therapeutics, Ms. Chapman is leading the company?s development of next-generation CAR T-cell therapies that address multiple mechanisms of resistance to deliver therapies to people living with cancer.

Since joining CARGO in May of 2022, she has rapidly scaled the organization to advance its pipeline, executed on critical manufacturing milestones and successfully led her team to raise an upsized $200 million Series A financing. Prior to joining CARGO, Ms. Chapman spent 15 years at Genentech where she served as Senior Vice President, Business Unit Head and was responsible for delivering the P&L across the oncology, hematology, neurology, immunology, ophthalmology, respiratory and rare diseases business units. Ms. Chapman began her biopharma career with Syntex Laboratories and in 1994 she joined Gilead Sciences as one of the first commercial hires where she was responsible for the launch of the company?s first commercial medicine and was a key contributor during its rapid growth from clinical stage start-up to commercial enterprise.